Clinical Trial Search

Primary: Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24 — 0; 0; 0 percentage of…

Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02

Primary: Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section — 15.5; 32.0 MED, mg — p=0.0117

Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants

Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28 — -10.76; -19.74 scores on a scale

Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants

Primary: Percent Change in Alanine Aminotransferase (ALT) Level — 11.99; -7.99 percentage change

Primary: Change From Baseline on the Children's Depression Rating Scale-Revised (CDRS-R) Total Score — -21.03; -22.42 units on a scale — p=0.5587

Primary: Qualification Rate for Permanent System Implant at the End of the Initial Trial Evaluation Period — 103; 93 Participants — p=0.0003

Primary: 30-day Point Prevalence Abstinence, Complete-case — 28.2; 21.1 Percentage of participants — p=<.001

Primary: UBT Values at Baseline and 8 Weeks — 161.64; 158.54; 49.42; 73.37 UBT value

Primary: Change From Baseline in VHI-10 Score After 4 Sessions of Voice Therapy — 7 score on a scale — p=.0076

Primary: Change in Body Weight — -5.78; -5.80; -1.76; -1.54 kg — p=.98

Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall)

Primary: Change From Baseline in Nasal Polyp Score at Week 16 — 0.20; -0.10; 0.14 score on scale — p=0.979